EQT-Backed Biotech Firm Evommune Raises $150 Million in IPO

Evommune Inc., a biotechnology company targeting chronic inflammatory diseases, raised $150 million in an initial public offering, adding to the list of companies that have been able to proceed with listings despite the US government shutdown.